Akkermansia muciniphila
A mucin-degrading gut bacterium that is depleted in obesity and metabolic disease. The counter-intuitive part is that the PASTEURIZED (dead) form outperformed the live one in trial.
Akkermansia muciniphila quick facts
| Suggested dose | 10 billion pasteurized cells daily in the trial protocol. |
| How often | Daily |
| Who it's for | Metabolic dysfunction alongside the actual levers — training, protein, sleep. |
The pasteurized form is what was used in the human pilot, which is counterintuitive — killing it did not abolish the metabolic benefit, suggesting a surface protein rather than colonization is the active principle. That pilot showed improved insulin sensitivity and reduced liver enzymes. Early, expensive, and one of the more scientifically interesting probiotics available.
How Akkermansia muciniphila actually works
Lives in the mucus layer and stimulates the goblet cells to produce more of it — so it actively thickens the barrier rather than merely occupying space. Its abundance correlates inversely with obesity, type-2 diabetes and inflammatory bowel disease across multiple human cohorts, and it is one of very few organisms with a mechanistically specific case rather than a general one.
Where to get Akkermansia muciniphila
Find Akkermansia muciniphila on iHerb →The evidence for Akkermansia muciniphila
Graded by what exists behind each claim.
✅ Clinically validated
- A randomized, placebo-controlled human trial in overweight/insulin-resistant adults found pasteurized Akkermansia improved insulin sensitivity, reduced insulinemia and lowered total cholesterol, with reductions in liver enzymes and inflammatory markers.
- Safety and tolerability were confirmed in that trial. It is one study — a good one, but one.
📊 Correlative data
- Low Akkermansia abundance is consistently associated with obesity, type-2 diabetes and IBD across cohorts.
🧪 Theoretical / extrapolated benefits
- The membrane protein Amuc_1100 signals through TLR2 and improves gut barrier integrity, which survives pasteurization and is the leading explanation for why heat-killed worked better.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Akkermansia muciniphila actually does
This organism lives in the mucus layer and eats it. Akkermansia muciniphila is a Gram-negative anaerobe of the phylum Verrucomicrobia that uses MUC2 mucin — the gel-forming glycoprotein your goblet cells secrete — as its carbon and nitrogen source, which is why it sits in the mucus rather than in the lumen and why it is typically a few percent of a healthy stool sample. Nothing else on this shelf occupies that niche.
The named target is Amuc_1100, and the receptor is TLR2. A single outer-membrane protein isolated from this organism reproduces much of what the whole cell does: it interacts with Toll-like receptor 2 and improves gut barrier function in mice Plovier 2017. TLR2 pairs with TLR1 or TLR6, signals through MyD88, and the read-out is a controlled, low-grade innate signal at the epithelium rather than an inflammatory one. That protein is the reason the dead product works.
Why killing it makes it better, stated properly. Pasteurization destroys the organism and leaves Amuc_1100 intact, and in obese and diabetic mice the pasteurized preparation had a greater capacity to reduce fat mass, insulin resistance and dyslipidemia than the live one Plovier 2017. A live bacterium has to arrive alive, find a niche, and compete. A heat-stable protein ligand has to survive a stomach and touch a receptor. The second job is much easier, and the product that does it is the one you cannot kill by leaving it in a hot car.
The second mechanism nobody prints: it feeds other people's bacteria. Degrading mucin releases sugars and produces acetate and propionate. Acetate is the substrate that butyrate producers use for cross-feeding, so a mucin specialist can raise colonic butyrate without making any butyrate itself. That makes this organism a hub rather than a widget, and it also means its effect depends on who else is in the room.
The paradox, and the honest resolution. A bacterium that eats the mucus barrier is being sold to thicken the mucus barrier. Both can be true, because mucin turnover stimulates goblet cells to secrete more — but the balance is conditional, and there is a demonstration of it going the other way: in gnotobiotic mice carrying a defined eight-species community, adding A. muciniphila to Salmonella-infected animals raised histopathology scores, raised IFN-gamma, IP-10, TNF-alpha, IL-12, IL-17 and IL-6 mRNA, and put 10-fold more Salmonella into the mesenteric lymph nodes; goblet cell numbers fell and correlated inversely with IFN-gamma at r² = -0.86, P < 0.001 Ganesh 2013. Same organism, opposite sign. The variable is what else is in the gut.
Cell, rodent, human — and where it stops
Cells and mice, and the mice are where the mechanism was made. Amuc_1100 was purified, shown to engage TLR2, and given orally to obese and diabetic mice alongside live and pasteurized whole cells; pasteurization improved rather than abolished the metabolic effect Plovier 2017. The enabling step in that paper is easy to miss and commercially decisive: the organism was grown on a synthetic medium rather than on mucin, which is what made a human product possible at all.
The human trial, with its real numbers. Forty overweight or obese insulin-resistant adults were randomized to 1010 A. muciniphila daily — live or pasteurized — or placebo, by mouth, for three months; 32 completed. Against placebo, the pasteurized arm improved insulin sensitivity by 28.62 ± 7.02% (P = 0.002), cut insulinemia by 34.08 ± 7.12% (P = 0.006) and lowered plasma total cholesterol by 8.68 ± 2.38% (P = 0.02). Body weight fell 2.27 ± 0.92 kg, which did not reach significance at P = 0.091 Depommier 2019. The live arm did not separate from placebo.
The second human trial, which changed the question. Fifty-eight people with overweight or obese type 2 diabetes took a different strain for 12 weeks alongside lifestyle advice. The result split by baseline: people who started with LOW native A. muciniphila colonized well and lost body weight and fat mass and lowered HbA1c; people who already had plenty colonized poorly and improved on nothing Zhang 2025. That is not a subgroup dredge, it was the paper's thesis and it was checked in germ-free mice.
The obstacle is the population, and it is unusually explicit here. Every human number above comes from people who were insulin-resistant, overweight or diabetic. Insulin sensitivity improving by 29% is a statement about someone whose insulin sensitivity had 29% of room in it. A lean, insulin-sensitive 30-year-old has no such room, has never been studied, and — if the baseline finding holds Zhang 2025 — is also the person most likely to already carry the organism and therefore least likely to respond.
The second obstacle is the size of the file. Thirty-two completers in one exploratory trial designed primarily to show the thing was tolerable Depommier 2019, plus 58 people on a different strain Zhang 2025. Ninety people is not a settled question; it is a good start that the marketing has already spent.
Akkermansia muciniphila — which form, and does it matter
Pasteurized beats live, and that is the entire buying decision. Both were given in the same trial at the same dose for the same three months, and only the pasteurized arm moved the endpoints Depommier 2019. This is the reverse of every other probiotic argument you have read, and it means the usual quality signals — refrigeration, CFU count, viability guarantee — are pointing you at the arm that failed.
A CFU number on a pasteurized product is a number that cannot exist. Colony-forming units are, by definition, cells that grow into a colony. Heat-treated cells do not. The correct unit for this product is total cells, counted by flow cytometry or by qPCR, and the trial dose was 1010 cells per day Depommier 2019. If a label says CFU and also says pasteurized, one of those two statements is wrong.
Two trials, two strains. The Belgian work used the type strain grown on a synthetic, animal-free medium Plovier 2017 Depommier 2019; the diabetes trial used a different isolate Zhang 2025. Strain designations for this organism are not decoration — they determine mucin-degrading capacity and Amuc_1100 expression — and a bottle that names no strain is inviting you to assume it is the one in the paper.
What the growth medium was matters more here than usual. An organism whose food is mucin can be grown on mucin, and mucin is an animal product. The synthetic-medium version is the one with the safety and efficacy data behind it Plovier 2017, and that fact is printed almost nowhere.
What would have to be true, and how you would know it was not
1. Fasting insulin moves before the scale does. In the trial, insulinemia fell 34% at P = 0.006 while body weight fell 2.27 kg at P = 0.091 Depommier 2019 — the hormone signal was cleaner than the weight signal. So predict fasting-insulin down at 12 weeks in someone whose baseline is raised, with the lipid-panel showing a single-digit-percent fall in total cholesterol, and predict body weight does not move enough to notice. Retest at 12 weeks, not sooner.
2. The prediction that cuts against the product. In an adult who is already insulin-sensitive — fasting insulin under about 6 µIU/mL, a normal HbA1c, a normal waist — predict nothing measurable at 12 weeks: no change in fasting-insulin, hba1c or lipid-panel. Every human result belongs to metabolic dysfunction, and the trial that looked hardest found that the people who most look like healthy controls are also the people it colonizes worst Zhang 2025.
3. A stool test should forecast your response, and this is testable today. If baseline abundance governs colonization Zhang 2025, then anyone whose 16S stool report already shows high Akkermansia should be predicted a non-responder before spending anything. That prediction is falsifiable with one stool test and 12 weeks, and no supplement company has ever offered it.
4. Liver enzymes are the place to look for a second signal. Metabolic improvement of this shape usually shows up in ggt and ALT before it shows up anywhere else. Predict a fall only in people whose baseline is above the reference range, and predict nothing at all in people whose enzymes are already normal — a marker with no abnormality cannot improve.
What nobody has tested yet
Nobody has given a human the protein. Amuc_1100 alone reproduced the metabolic effect in mice Plovier 2017, and the human trial gave whole cells Depommier 2019. A purified-protein arm is the obvious next study, it would separate the ligand from everything else in a bacterial cell wall, and seven years later it has not been run.
Nobody has powered live against pasteurized for efficacy. The comparison exists inside an exploratory trial whose primary purpose was safety and tolerability Depommier 2019. “Live did not separate from placebo in 32 completers” and “live does not work” are different statements, and the site sells the second one because nobody has funded the first.
Nobody has measured a human mucus layer on this. The entire barrier argument — thicker mucus, tighter junctions — rests on rodent histology. Mucus thickness is measurable in a human biopsy, and no supplement trial has taken one.
And nobody has tested it in inflamed bowel, which is exactly where the mechanism could invert. The gnotobiotic experiment that made this organism look harmful required an enteric pathogen to be present Ganesh 2013. Whether that translates to human colitis is unknown, untested, and the single most important unanswered safety question about a mucin-degrading probiotic.
Akkermansia muciniphila — its own safety story, not its category's
The dead product removes the risk that defines this category. The standard probiotic warning — bacteremia in people with central lines, in critical illness, in immunosuppression — is about a live organism crossing a compromised barrier. A pasteurized preparation contains no viable organism, so that risk is not reduced, it is absent. This is the rare case where the better-evidenced form Depommier 2019 is also the safer one, and it is worth saying out loud because most people buy the live version believing the opposite.
The risk that belongs to this organism specifically is the mucus layer. It is a mucin degrader. In an animal model with a defined community and an enteric pathogen, its presence reduced goblet cell numbers and worsened inflammation Ganesh 2013. Nobody has shown that in a person, and nobody has looked. Anyone with active inflammatory bowel disease is deciding without data, and the mechanistic direction of the missing data is not reassuring.
It lowers glucose measures, so it stacks with drugs that do the same. Insulinemia fell by a third in the trial population Depommier 2019, and HbA1c fell in the low-baseline responders of the diabetes trial Zhang 2025. On metformin, a GLP-1 agonist, a sulfonylurea or insulin, that is additive rather than parallel. Test before and after rather than assuming a bacterium is too small to matter.
The honest limit is duration. Three months Depommier 2019 and twelve weeks Zhang 2025 are the longest human exposures on record. Nobody has taken this for a year under observation. A daily dose of an organism whose job is to remodel your mucus layer is not a thing to assume is neutral over a decade because it was tolerated over a season.
Sources read for this page
- Depommier C, Everard A, Druart C, et al. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nature Medicine 2019 · PMID 31263284
- Plovier H, Everard A, Druart C, et al. A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice. Nature Medicine 2017 · PMID 27892954
- Zhang Y, et al. Akkermansia muciniphila supplementation in patients with overweight/obese type 2 diabetes: Efficacy depends on its baseline levels in the gut. Cell Metabolism 2025 · PMID 39879980
- Ganesh BP, Klopfleisch R, Loh G, Blaut M. Commensal Akkermansia muciniphila exacerbates gut inflammation in Salmonella Typhimurium-infected gnotobiotic mice. PLoS One 2013 · PMID 24040367
How you would know if it worked
The one well-run human trial measured exactly this: pasteurized cells improved insulin sensitivity, reduced insulinemia and lowered total cholesterol in overweight insulin-resistant adults, with reductions in liver enzymes and inflammatory markers alongside. That is a single trial in roughly 32 completers, so the numbers are the only honest way to hold this product to what its own evidence claims.
- hs-CRP (High-Sensitivity C-Reactive Protein) Retest: 3 months after intervention; repeat any high value.
- Fasting Insulin Retest: Every 3–6 months, or 8–12 weeks after an intervention.
- Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) Retest: Every 3–6 months on androgens; annually otherwise.
The cheapest panel carrying hs-CRP (High-Sensitivity C-Reactive Protein) and at least one other of these is High Ferritin — Overload or Inflammation?, at $89 — the panel is named for a different question, and the marker is the same marker. That is the whole cost of finding out.
Draw before you start, not after. A result with nothing to compare it to answers nothing.
Akkermansia muciniphila — safety & side effects
- Well tolerated in trials; GI upset is the main report.
- Pasteurized (non-viable) product has the better trial evidence, which is unusual for a probiotic. Long-term safety has not been characterized — the trials run weeks to months, not years. That is a real limit on what anyone can tell you about daily use for a decade.
The same on every page it applies to. Read it here; it is not repeated research.
- Bloodstream infection has occurred in immunocompromised patients, in critical illness, and in people with central venous catheters. That is the one contraindication here that is not theoretical. Otherwise: expect one to two weeks of gas and bloating while things settle.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this against it with a pharmacist or doctor — pharmacists are underused and free.
- When to take it, and what to take it with
- Which form actually absorbs
- Who it's worth it for
- Coach Cam's stacks and notes
- Fasted or with food, and when in the day
- Morning or night, and why that window
- Around training, or deliberately away from it
- What it must not share a window with
Everything above is free and stays free. Skool is where it becomes a plan — Akkermansia muciniphila in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Akkermansia muciniphila
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| Complete Blood Count (CBC) with Differential | Anemia is the commonest sign of a gut absorbing badly |
| Ferritin | Iron is the first thing malabsorption takes |
| Vitamin B12 | The second thing, and the one with permanent consequences |
| hs-CRP (High-Sensitivity C-Reactive Protein) | Separates inflammatory bowel disease from IBS |
The Gut Health & Absorption panel covers these in one order — 11 markers, $208.80 with the discount applied.
Check results you already have → · All 103 markers A–Z
Akkermansia muciniphila — frequently asked questions
What is Akkermansia muciniphila?
A mucin-degrading gut bacterium that is depleted in obesity and metabolic disease. The counter-intuitive part is that the PASTEURIZED (dead) form outperformed the live one in trial.
What is the suggested dose of Akkermansia muciniphila?
10 billion pasteurized cells daily in the trial protocol. This is a general reference for education only — statements have not been evaluated by the FDA and this is not medical advice.
Where can I find Akkermansia muciniphila dosing and the full breakdown?
The suggested dose and the full evidence — clinical, correlative and theoretical — are on this page. What's inside Skool is when to take it, which form actually absorbs, the brand worth buying and Coach Cam's stacks.
Where can I buy Akkermansia muciniphila?
Coach Cam sources Akkermansia muciniphila from vetted, top-rated brands on iHerb — use the buy link on this page.
Akkermansia muciniphila inside a finished plan
One arm of 1 Protocol Blueprint, free to read in full.
What Akkermansia muciniphila is used for
Akkermansia muciniphila appears under 1 goal in the goal router.
Related Gut & Digestion supplements
Where this goes next
Akkermansia muciniphila is the microbiome arm of this plan. The page above is the free breakdown of one compound; the plan it belongs to — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.